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Abstract
Background: The aim was to measure flagellin concentrations in the expectorations of CF patients and to examine
whether there are correlations with the level of respiratory insufficiency and inflammation.
Methods: Sputum samples from 31 adult patients chronically colonized with P. aeruginosa were collected and
analysed for their content of flagellin and IL-8. Clinical data were extracted from patient files.
Results: Regardless of whether patients are colonized with mucoid strains or not, they carry clones of P. aeruginosa
that express flagellin. While flagellin was present in airways of all of our CF patients, it is difficult to ascertain its
contribution to inflammation (IL-8) and lung function deterioration.
Conclusions: This is the first demonstration that flagellin is present in the sputum of patients. Thus, attempts to
down regulate inflammation by the use of TLR5 (flagellin receptor) antagonists remain a possibility. However, this
result needs to be extended to a larger number of patients to validate it for future research on this subject.
Keywords: Sputum, Chronic inflammation, Infection, Respiratory function
Background
Cystic fibrosis (CF) is characterized at the lung level by a
florid chronic inflammatory response which is due to many
factors, including proteases such as neutrophil elastase but
also chronic respiratory infection, involving most frequently
Pseudomonas aeruginosa (Pa) in adult patients [1,2]. Pul-
monary exacerbations occur, possibly due to changes in the
metabolism or phenotype of Pa [3,4], and contribute to de-
terioration of the patient’s respiratory status. Of note, the
effect of gender and the menstrual cycle has been shown to
affect Pa phenotypes [5]. Thus chronic colonization of the
lungs with Pa is considered to be the leading cause of re-
spiratory morbidity and mortality in CF patients [6,7].
The inflammatory response to Pa is believed to be medi-
ated mainly by Toll-like receptors (TLR) 4 and 5 [8-10],
and possibly by TLR2 [11]. Thus it may be hypothesized
that both lipopolysaccharides (LPS) and flagellin expressed
and released by Pa play crucial roles in lung inflammation
since TLR4 and 5, are both expressed by alveolar
macrophages, neutrophils and respiratory epithelial cells
[11-14]. Some reports seem to indicate that flagellin is pos-
sibly an important agonist to initiate an inflammatory reac-
tion as LPS is believed to be poorly recognized by human
respiratory airway cells [15,16]. Nevertheless, in acute lung
infections of mice, the recognition of LPS by the airways
appears to be effective in generating a protective inflamma-
tory response [10], therefore one cannot exclude a role for
LPS in inducing the chronic inflammatory response. In-
deed, proinflammatory lipid A alterations have been re-
ported in Pa strains of CF patients [17].
In contrast to lipid A, the signaling part of the LPS mol-
ecule, whose expression is essential for bacteria viability,
the expression of flagellin by Pa colonizing the lungs may
fluctuate and non flagellated strains are frequently isolated
from CF patients [18]. For example, Pa growing in muco-
purulent human respiratory mucus from CF patients re-
presses the expression of its flagellin [19], in response to
the presence of neutrophil elastase in such mucus [20]. It is
hypothesized that these changes are an attempt by the bac-
terium to minimize the innate immune response against it.
Furthermore neutrophil elastase is also able to directly
cleave flagellin, resulting in the loss of its ability to induce
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an innate host response [21]. In addition, it is thought that
Pa within a microcolony or biofilm-growing mucoid (algin-
ate-producing strains) possess a unique phenotype quite
different from their planktonic counterparts [22,23], repres-
sing genes for flagellar biogenesis in addition to others
[24,25]. Hence one can easily conclude that flagellin may or
may not be expressed depending on the environment, and
thus may or may not play a role in the chronic inflamma-
tory response.
The aim of the present study was thus to measure flagel-
lin concentrations in the expectorations of CF patients and
to examine whether correlations exist with the presence or
absence of flagellin and the level of respiratory insufficiency.
This is an important question as in case of the presence
and of a positive correlation one can envisage anti-
inflammatory treatment based on the inhibition of the
interaction between flagellin and TLR5 by mutants of fla-
gellin or anti-TLR5 small molecules. Indeed, it has been
already shown with human respiratory epithelial cells that a
mutant of flagellin that activates TLR5 poorly, was able to
reduce IL-8 synthesis triggered by wild-type flagellin [26].
Methods
Patients
Thirty-one adults with CF attending the CF centre at
Cochin University Hospital, Paris were enrolled between
May 2011 and October 2011 during a planned visit. None
of the patients was hospitalized. Criteria for inclusion were:
age older than 18 and chronic colonization with Pa (de-
fined according to the Lee criteria [27] when airway sam-
ples were Pa culture positive in > 50% of the explored
months over the last 12 months). Clinical data were ex-
tracted from patient files, including demographic data (age
and gender), CFTR genotype, exocrine pancreatic insuffi-
ciency, diabetes, body mass index and pulmonary function.
Pulmonary function tests were performed on the day of the
outpatient visit. Forced expiratory volume in one second
(FEV1) and forced vital capacity (FVC) were expressed as
percentages of the predicted value (% pred.). Patients were
considered stable or in exacerbation according to Fuchs cri-
teria [28]. They gave their informed consent for participa-
tion in the study which was conducted in accordance with
the Declaration of Helsinki and French law and was ap-
proved by the Institutional Review Board for Medical Re-
search (CCTIRS # 08–370). In addition, patients provided
consent for the publication of their data.
Sputum collection and treatment
All sputa were spontaneously expectorated and were col-
lected in a sterile container. A fraction of the each sputum
sample was processed by the Clinical Microbiology Labora-
tory of the hospital for microbiological analysis. Pa was
quantified by platting serial dilutions (1/2, 1E-3, 1E-5) of
fluidified (Digest’Eur, Eurobio, Courtaboeuf, France) sample
on non-selective (COH and PVX, BioMerieux, Marcy
L’Etoile, France) and selective (Dirgalski, BioRad, Marnes
La Coquette, France) solid media. Plates were incubated for
up to 7 days. Quantification and mucoid phenotype (ab-
sence/presence of viscous and slimy colonies) of each Pa
isolate was reported upon bacterial isolation. The other
fraction of the sputum was left on ice and processed within
two hours from the start of the collection. All material was
transferred to a Petri dish to discard saliva, then the sputum
was collected and vortexed for 1 min with v/v RIPA lysis
buffer 2× (300 mM NaCl, 50 mM HEPES, 10 mM EDTA,
0.2% SDS, 2% Nonidet P40, 0.1% Deoxycholate), supple-
mented with Complete, EDTA free-protease inhibitor cock-
tail (Roche Diagnostics). Samples were centrifuged and the
supernatant was stored at −80°C.
Flagellin quantification
Flagellin amounts in the expectorations were quantified by
Western Blot analysis by comparing the band intensity to a
standard curve of purified Pseudomonas flagellin, purified
as described previously [26].
For the quantification, total protein concentrations in ex-
pectorations were measured using Pierce BCA protein
assay and then solubilized with Laemmli buffer prior to
electrophoresis. Four concentrations of protein (1, 2.5, 5
and 10 μg/well) from one expectoration and the standard
curve of flagellin (0.1, 0.25, 0.5, and 1.0 ng/well) were
loaded on a 10% acrylamide gel and fractionated by SDS-
PAGE. Proteins were electrotransferred to a polyvinylidene
difluoride membrane (Immobilon, Millipore Corp., Bedford,
MA) and probed using specific antibody against Pseudo-
monas flagellin which recognizes the two different types,
flagellins a and b of Pa which share large stretches amino
acid sequences [29]. Bound antibody was detected using
the ECL + immunoblotting detection system (Thermofisher,
Rockford, USA) according to the manufacturer’s instruc-
tions. Molecular masses were estimated from calibration
standards included in each gel.
Band intensity was analyzed by using ImageJ software
version 1.45 g. A standard curve of purified flagellin was
constructed using a linear curve-fit by plotting the band
intensity for each standard on the y-axis against the con-
centration on the x-axis. Flagellin concentrations in expec-
torations were calculated using the equation of the
standard curve. This calculation was made for each of the
three or four concentrations of proteins, and the values
were averaged. To normalize results, flagellin concentra-
tions were expressed for 100 μg of total proteins. Represen-
tative immunoblots are shown in Figure 1.
Interleukin-8 determination
IL-8 concentrations in expectorations were determined
using Duo-Set ELISA kit (R&D systems, Minneapolis,
USA).
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Statistical analysis
The analysis of variance (ANOVA) was performed for mul-
tiple comparisons with Bonferroni post test. For comparison
of two samples Student’s t test was applied. A p value <0.05
was considered significant. GraphPad Prism 5 (GraphPad
Software Inc, San Diego, CA) was used for the analysis.
Results
Patient demographics, clinical status and flagellin
concentrations
The clinical characteristics of the patients and results of
flagellin concentrations in sputum are shown in Table 1.
Patients were classified in two groups of respiratory in-
sufficiency according to their FEV1: severe respiratory
insufficiency below 45% pred. and moderate respiratory
insufficiency above 45% pred.
The mean age of the patients with severe respiratory in-
sufficiency was 31.8 ± 9.2 years, it was of 31.5 ± 6.6 for those
with moderate respiratory insufficiency (ns). We did not
observe a clear-cut difference in the CFTR genotype be-
tween these two groups of patients (8/17 of the patients
with severe disease (47%) were F508del homozygotes com-
pared to 6/14 of the patients with moderate disease (43%)).
Comparisons of the two groups for the different clin-
ical parameters such as pancreatic insufficiency (PI) vs
pancreatic sufficiency (PS), cystic fibrosis-related dia-
betes (CFRD) and body mass index (BMI) did not dem-
onstrate obvious differences as well (Table 1).
IL-8 measurements, done as a proxy for the ongoing
inflammatory response also did not demonstrate a
difference according to the category of respiratory insuf-
ficiency of our patients (Table 1). The concentrations
ranged from 966 to 10,848 ng/100 μg proteins.
Finally, for the parameter constituting the aim of our
study, i.e. the concentration of flagellin in the sputum, the
difference was not statistically significant between the two
groups, with mean values ± sd of 14.0 ± 15.6 ng/100 μg pro-
teins for patients with severe respiratory insufficiency and
of 9.1 ± 10.1 ng/100 μg proteins (Table 1).
Correlation of flagellin concentrations in sputum with
respiratory insufficiency
In order to visualize differently a possible correlation be-
tween flagellin concentrations and patient respiratory insuf-
ficiency, we considered two groups, i.e. a group with
flagellin concentrations lower than 10 ng/100 μg proteins
(20 patients), and a group with flagellin concentrations
higher than 10 ng/100 μg proteins (11 patients). The
mean ± sd values for flagellin were thus 4.2 ± 2.0 and
25.5 ± 14.7 ng/100 μg proteins, respectively (Table 2).
For the group of patients with low flagellin concentra-
tions the mean age was 31.1 ± 6.8 years, with a 50/50
male/female ratio, and for the group of patients with
high flagellin concentrations the mean age was 32.6 ±
10.1 years, with 54/46 male/female ratio. Means ± sd
values were not statistically significant.
In fact for FEV1 there was no significant differences as
well, values being of 52.1 ± 18.1% of predicted and 42.0 ±
17.5% (means ± sd) of predicted for the low and high
flagellin concentration groups, respectively. Thus, higher
flagellin concentrations did not automatically suggest
more severe disease.
We also assessed whether high concentrations of flagellin
may be linked with pulmonary exacerbations i.e. acute
worsening of CF symptoms caused by infection and that
lead to the need for additional antibiotic treatment [7]. Five
patients had mild pulmonary exacerbation requiring an
antibiotic IV course at home, none was hospitalized. No
correlation was observed as patients with exacerbation had
very different concentrations of flagellin in their expector-
ation, ranging from 0.64 to 60.65 ng/100 μg proteins, in fact
the two extreme values of the whole group of 31 patients.
Among the 20 patients with flagellin concentrations lower
than 10 ng/100 μg proteins, 4 patients had exacerbations,
compared to only one patient among the 11 other patients
whose flagellin concentrations were higher. Thus, there
was no correlation between flagellin concentrations and
exacerbations.
Analysis of the expectorations did not demonstrate
differences among the total proteins in sputum between
the two groups (Table 2). As well, no correlation (r2 =
0.02) could be found between flagellin concentrations
and bacterial numbers.
Figure 1 Representative western blots of three sputum extracts
containing low (n°36), medium (n°25) and high (n°9) flagellin
concentrations. Four concentrations of protein (1, 2.5, 5 and 10 μg/
well) from 3 different expectorations and standard curve of flagellin
(0.1, 0.25, 0.5, and 1.0 ng/well) were loaded on 10% acrylamide gel
and fractionated by SDS-PAGE (see Methods). Note i) that the
recombinant non glycosylated flagellin (right hand side) has a
molecular weight lower (40 kD) than the native flagellin (left hand
side) present in the sputum (49 kD) and corresponding to flagellin
type b, and 2) the presence a faint band with a 40 kD mw observed
for patients 25 and 9, and corresponding to flagellin type a.
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Interestingly, mucoid strains were present in 4/20
patients (20%) with low flagellin concentrations and
even more in 4/11 (36%) patients with high flagellin
concentrations. As discussed previously the general state-
ment is made that mucoid strains lose the ability to
make flagellin, however regardless of whether the patient
Table 1 Patients with severe vs moderate clinical severity
N° Sex FEV1 FVC PI/PS CFRD BMI IL-8 Flagellin
(% pred.) (% pred.) kg/m2 (ng/100 μg prot) (ng /100 μg protein)
Patients with severe respiratory insufficiency
2 F 30 38 PI N 15.04 2189.72 11.23
3 M 24 55 PI Y 24.77 3163.50 5.76
8 M 44 43 PI N 20.01 3064.52 2.92
9 M 20 39 PI Y 20.68 1866.86 23.29
10 M 40 62 PI Y 16.61 4009.74 33.78
13 M 44 60 PI N 19.35 5851.31 8.58
14 M 37 69 PS N 20.43 966.36 31.53
15 M 30 46 PI N 18.94 7007.48 13.40
16 F 27 37 PI N 21.22 10848.53 60.65
17 M 29 57 PI N 22.40 2754.30 16.75
20 M 43 58 PI N 21.26 2203.66 4.24
21 F 43 58 PI N 20.50 3596.65 6.50
25 F 42 60 PI Y 33.20 4089.03 3.68
31 M 38 58 PI N 21.41 2681.30 7.17
34 F 18 22 PI Y 21.68 3050.02 1.74
35 F 41 54 PS N 19.20 1735.26 6.12
36 F 41 61 PI N 18.26 3764.78 0.64
Mean M: 58.8% 34.76 51.59 PI: 88.2% CFRD: 29.4% 20.88 3696.65 14.00
±SD 8.78 12.11 3.87 2361.02 15.60
Patients with moderate respiratory insufficiency
4 F 66 81 PI N 19.89 1114.53 12.66
5 F 66 79 PI Y 25.33 1680.15 4.80
6 F 64 73 PS N 26.67 2748.14 5.10
7 M 60 68 PI N 22.59 2548.47 5.62
11 F 91 106 PI N 21.64 1832.33 3.41
12 M 59 79 PI Y 25.69 7971.28 2.68
18 F 70 84 PI N 25.81 2289.97 3.62
19 F 73 82 PI Y 17.75 2142.72 30.01
22 M 75 108 PI N 19.59 4286.10 3.82
23 F 55 89 PI Y 20.26 1648.29 13.88
24 M 46 74 PI Y 20.86 3194.50 4.50
26 M 55 55 PI Y 23.66 3217.85 32.80
37 F 57 82 PI Y 23.31 4453.10 1.07
38 M 76 91 PI N 22.99 3437.08 2.73
Mean M: 42.8% 65.21 82.21 PI: 92.9% CFRD: 50% 22.57 3040.32 9.05
±SD 11.35 13.80 2.70 1725.97 10.15
Comparison of two groups of patients, a group with clinical severity defined as severe (18 patients), and a group with clinical severity defined as moderate
(13 patients).
FEV1 (% pred.) and FCV (% pred.) are forced expiratory volume in one second and forced vital capacity (expressed as percentage of the predicted value),
respectively. Pancreatic insufficiency (PI) vs pancreatic sufficiency (PS); cystic fibrosis-related diabetes (CFRD); Body mass index (BMI).
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Table 2 Patients with high vs low flagellin concentrations
N° Sex Status Mucoid/non
mucoid
FEV1 FVC Total proteins IL-8 Flagellin
Stable/Exacerbation (% pred.) (% pred.) (mg/ml) (ng/100 μg prot) (ng/100 μg protein)
Patients with flagellin sputum < 10 ng/100 μg protein
3 M Stable Non mucoid 24 55 6.58 3163.50 5.76
5 F Stable Non mucoid 66 79 3.21 1680.15 4.80
6 F Exacerbation Mucoid 64 73 4.57 2748.14 5.10
7 M Stable Non mucoid 60 68 9.34 2548.47 5.62
8 M Exacerbation Non mucoid 44 43 3.84 3064.52 2.92
11 F Stable Non mucoid 91 106 3.15 1832.33 3.41
12 M Stable Non mucoid 59 79 4.39 7971.28 2.68
13 M Stable Non mucoid 44 60 11.8 5851.31 8.58
18 F Stable Non mucoid 70 84 4.17 2289.97 3.62
20 M Stable Non mucoid 43 58 8.68 2203.66 4.24
21 F Stable Mucoid 43 58 5.91 3596.65 6.50
22 M Stable Non mucoid 75 108 5.87 4286.10 3.82
24 M Stable Non mucoid 46 74 7.25 3194.50 4.50
25 F Stable Non mucoid 42 60 4.91 4089.03 3.68
31 M Stable Mucoid 38 58 4.70 2681.30 7.17
34 F Exacerbation Non mucoid 18 22 4.22 3050.02 1.74
35 F Stable Non mucoid 41 54 7.83 1735.26 6.12
36 F Exacerbation Non mucoid 41 61 6.71 3764.78 0.64
37 F Stable Mucoid 57 82 8.93 4453.10 1.07
38 M Stable Non mucoid 76 91 6.59 3437.08 2.73
Mean M: 50% non.mucoid:.80% 52.10 68.65 6.13 3382.06 4.24
±SD 18.11 20.39 2.30 1491.93 2.03
Patients with flagellin sputum > 10 ng/100 μg protein
2 F Stable Mucoid 30 38 7.90 2189.72 11.23
4 F Stable Non mucoid 66 81 3.25 1114.53 12.66
9 M Stable Mucoid 20 39 8.22 1866.86 23.29
10 M Stable Mucoid 40 62 4.11 4009.74 33.78
14 M Stable Non mucoid 37 69 5.38 966.36 31.53
15 M Stable Non mucoid 30 46 6.42 7007.48 13.40
16 F Exacerbation Non mucoid 27 37 5.87 10848.53 60.65
17 M Stable Non mucoid 29 57 2.79 2754.30 16.75
19 F Stable Non mucoid 73 82 5.14 2142.72 30.01
23 F Stable Mucoid 55 89 6.81 1648.29 13.88
26 M Stable Non mucoid 55 55 8.44 3217.85 32.80
Mean M: 54.5% Non mucoid:.63.6% 42.00 59.55 5.85 3433.31 25.45
±SD 17.52 18.80 1.94 2981.86 14.65
Comparison of two groups of patients, a group with flagellin concentrations lower than 10 ng/100 μg proteins (20 patients), and a group with flagellin concentrations higher than 10 ng/100 μg proteins (11 patients).
FEV1 (% pred.) and FCV (% pred.) are forced expiratory volume in one second and forced vital capacity (expressed as percentage of the predicted value), respectively.
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carried or not a mucoid strain of Pa, the mean concen-
tration of flagellin found in the sputum samples was
similar, i.e. 13.6 ± 11.4 vs 12.5 ± 15.2 ng/100 μg, respect-
ively. It should however be noted that the clinical labora-
tory reported the presence or not of a mucoid strain
which does not imply that when this phenotype was
present, the nonmucoid strain was absent.
Discussion
Flagellin is a potent activator of a broad range of cell
types involved in innate and adaptive immunity. Its rec-
ognition by TLR5 is involved in activating pulmonary
defenses against Pa that leads eventually to elimination
of this bacterium from the host. Thus, bacterial mutants
that lacked flagellin appeared to evade immune control
and were relatively slowly cleared from the lungs. Along
the same line, the loss of the TLR5 response has conse-
quences on the host response, that results in an impair-
ment of antimicrobial effectors [30].
The well known paradox is that the TLR5-flagellin
interaction is a major mediator of inflammation follow-
ing exposure to Pa. Indeed, Pa mutants which overpro-
duced flagellin, caused severe inflammation [31]. The
consequence is that some authors have proposed TLR5
as an anti-inflammatory target [32]. Interestingly, CF pa-
tients carrying the TLR5 premature stop codon had a
higher body mass index than CF patients homozygous
for the functional allele. This is some evidence that a
loss of TLR5 function resulting in reduced flagellin re-
sponsiveness is associated with improved health indica-
tors in adults with CF. Unfortunately, improvements in
lung functions were not statistically significant [32]. An-
other study demonstrates that flagellin induces the gen-
eration of myeloid-derived suppressor cells and suggest
that Pa uses this mechanism to undermine T cell–medi-
ated host defense in CF [33]. In summary, there is not a
clear picture about the beneficial or deleterious conse-
quences of TLR5-flagellin interaction in vivo. And in
fact, it was even not known whether flagellin was
present or not in the sputa of CF patients.
Conclusion
The present study although having a small sample size, al-
lows two conclusions. Firstly, it points out that possibly all
Pa colonized patients, regardless of whether the clinical la-
boratory indicates they are colonized with mucoid strains,
carry clones of Pa that express flagellin. This is the first
time that flagellin concentrations in the sputum of CF pa-
tients has been examined. Thus caution should be exercised
in concluding that patients with mucoid strains cease to
carry flagellin producing clones. This finding is consistent
with a recent report that there is significant “phenotypic”
heterogeneity of Pa populations in a CF patient [34]. Sec-
ondly, while flagellin seems to be always present in CF
airways, it is difficult to measure its contribution to inflam-
mation (IL-8 measurements) and lung function deterior-
ation, since we could not correlate amounts present with
the level of respiratory insufficiency nor with the presence
of a pulmonary exacerbation. However given that this agon-
ist has now been shown to be present in all patients we
studied, attempts to down regulate inflammation by the use
of TLR5 antagonists still remain viable.
Although we are aware that the present data are not
conclusive and need to be strenghtened, we believe that
their novelty (this is the first demonstration that flagellin
is present in the sputum of all patients studied) deserves
to be brought to the attention of the CF community.
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